Cantor Fitzgerald Starts NewLink Genetics (NLNK) at Buy; Late Stage Assets, Many Milestones

Cantor Fitzgerald initiates coverage on NewLink Genetics (NASDAQ: NLNK) with a Buy. PT $12.00.

Cantor analyst said, "A pipeline for major unmet medical needs. NewLink is a cancer immunotherapy company developing drugs for cancer, focusing on major unmet medical needs and collectively addressing multi-billion markets. Significant milestone calendar to boost visibility. With multiple products in trials, a steady stream of news could be forthcoming through 2013, including advancement of candidates, especially the HyperAcute program. Manufacturing is a differentiator. The HyperAcute vaccine program is allogeneic with the potential for a modest manufacturing process and cost structure, potentially mitigating production and commercial risk."

For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.

Shares of NewLink Genetics closed at $7.00 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cantor Fitzgerald Downgrades Better Home & Finance Holding (BETR) to Neutral
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald